Advances in the Treatment of FLT3-Mutated AML
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2017, Vol 1, Issue 1
Abstract
AML is a heterogeneous disease and is the most common acute leukemia in adults. It has an annual US incidence over 20,000 and death rate of over 10,000 per year. The 5-year remission rates after conventional induction therapy is 40% below 60 years and 10%-20% in older patients. FLT3-ITD mutation has been added to the WHO risk stratification as a predictor of poor prognosis. On April 28, 2017 FDA approved midostaurinin combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for treating adult newly diagnosed AML patients who are FLT3 mutation positive as detected by an FDA approved test. The FLT3 gene is located on chromosome 13q12, and the resultant protein is a member of the class III RTK family. The FLT3 RTK expression is normally limited to early myeloid progenitors and it appears to play a key role in the differentiation and maturation of hematopoietic precursors. FL binding to the receptor activates downstream signaling cascades, which mediate differentiation and growth. These pathways include the key intermediary proteins RAS, MEK, PI3K, AKT, and STAT-5 [1]. Over expression of FLT3 in cell lines results in increased pro¬liferation and decreased apoptosis [2]. FLT3 mutations occur as secondary events during AML clonal evolution [3] in approximately 30% of AMLs. In 23%, the mutations occur via ITD in the juxtamembrane domain and in 7% via point mutation usually in the Asp835 residue within the activation loop. Both muta¬tions result in constitutive activation of the kinase [2]. FLT3/ITD AML frequently presents with leukocytosis and normal cytogenetics and is more likely to arise de novo rather than out of an antecedent disorder such as MDS or a myeloproliferative neoplasm. FLT3 mutations frequently co-occurred with NPM1 and DNMT3A mutations (39%) and chromatin or RNA splicing gene mutations (15%), and were also associ¬ated with t(15;17) and t(6;9) translocations (35% and 80%, respectively).Patients with FLT3-ITD mutation are usually not cured with conventional chemotherapy [4]. They have higher induction death rate, a lower CR rate, increased risk of relapse, and adverse DFS, event-free survival, and OS [5].
Authors and Affiliations
Nahla A M Hamed
Keywords
Related Articles
- EP ID EP567427
- DOI 10.26717/BJSTR.2017.01.000139
- Views 183
- Downloads 0
Trained Innate Immunity: New Immunological Memory Mechanisms
Trained innate immunity attracts more and more attention in recent years. Innate immune memory is observed in natural killer cells, monocytes and macrophages after being trained by certain antigens and non-specific stron...
Magnetism Study in Transition Metal Doped Superatoms: TMLi12(TM=Sc-Fe)
Through unbiased global optimization and density functional theory method, a series of stable icosahedral magnetic TMLi12 (TM=Sc-Fe) clusters are identified, where the 3d transition-metal element is embedded at the cente...
Hydatid Cystic Disease of Lumbar Paraspinal Muscles
The larva of the tap worm Echinococcus Granulosus causes Hydatid Cystic disease in humans which is a common public health problem in many countries of the Middle east, Mediterranean, Australia and New Zealand [1,2]. The...
Titanium Plate Cranioplasty Induced Intravascular Papillary Endothelial Tumor: Case Report and Review of the Literature
Intravascular Papillary Endothelial Hyperplasia (IPEH) or Masson’s tumor are non-specific vascular lesions which enclose reactive proliferation of endothelial cells that arise in an organizing thrombus. These tumors are...
The Solid Core (Trephine) Bone Marrow Biopsy Needle; Advantages of Employing A Biopsy Needle with Core Retention Design
The technique of bone marrow trephine (solid core) biopsy was first introduced by Ghedini of Genoa in 1908 when he performed a surgical bone marrow biopsy on a patient to aid in the diagnosis of a hematologic disease. He...